Ovid Therapeutics Gestione
Criteri Gestione verificati 3/4
Ovid Therapeutics Il CEO è Meg Alexander, nominato in Sep2024, e ha un mandato di 1.75 anni. la retribuzione annua totale è $ 1.02M, composta da 50.4% di stipendio e 49.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.011% delle azioni della società, per un valore di $ 45.59K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 3.5 anni.
Informazioni chiave
Meg Alexander
Amministratore delegato
US$1.0m
Compenso totale
| Percentuale dello stipendio del CEO | 50.38% |
| Mandato del CEO | 1.8yrs |
| Proprietà del CEO | 0.01% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 3.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders
Summary Ovid Therapeutics receives a "Hold" rating as it pivots pipeline focus after soticlestat trial failures in rare epileptic syndromes. OVID reported positive phase 1 results for OV329, a next-generation GABA-AT inhibitor targeting drug-resistant focal onset seizures, with phase 2a trials planned for 2026. Pipeline includes KCC2 activators OV350 (IV) and OV4071 (oral) for neurological and psychiatric disorders, with key data and regulatory milestones expected through 2026. Recent financing extends OVID's cash runway into 2028, but clinical and regulatory risks remain for OVID's early-stage programs. Read the full article on Seeking AlphaOvid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Results from the phase 3 Skyway study, using soticlestat for the treatment of patients with Lennox-Gastaut Syndrome, expected by or before September 2024. The global Lennox-Gastaut Syndrome market is expected to reach $1 billion by 2030. Read the full article on Seeking AlphaWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Ovid Therapeutics press release (NASDAQ:OVID): Q2 GAAP EPS of -$0.21 beats by $0.04. Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 millionWe Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Ovid Therapeutics Inc.'s...Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Ovid Therapeutics Inc. ( NASDAQ:OVID ) shareholders will have a reason to smile today, with the analysts making...Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
It's been a good week for Ovid Therapeutics Inc. ( NASDAQ:OVID ) shareholders, because the company has just released...We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
If you want to know who really controls Ovid Therapeutics Inc. ( NASDAQ:OVID ), then you'll have to look at the makeup...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$24m |
| Dec 31 2025 | US$1m | US$515k | -US$17m |
| Sep 30 2025 | n/a | n/a | -US$36m |
| Jun 30 2025 | n/a | n/a | -US$38m |
| Mar 31 2025 | n/a | n/a | -US$24m |
| Dec 31 2024 | US$2m | US$484k | -US$26m |
Compensazione vs Mercato: La retribuzione totale di Meg ($USD 1.02M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.45M ).
Compensazione vs guadagni: La retribuzione di Meg è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Meg Alexander (45 yo)
Ms. Margaret Alexander, also known as Meg, is CEO of Ovid Therapeutics Inc. from January 1, 2026 and serves as its President since September 2024 and served as Chief Strategy Officer since June 2023 until...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.2yrs | US$1.93m | 2.02% $ 8.6m | |
| CEO, President & Director | 1.8yrs | US$1.02m | 0.011% $ 45.6k | |
| Chief Business & Financial Officer and Corporate Secretary | 5yrs | US$969.16k | 0.025% $ 105.6k | |
| Chief Scientific Officer | 3yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development | 4.9yrs | Nessun dato | Nessun dato | |
| Head of Epilepsy Research | 3.3yrs | Nessun dato | Nessun dato | |
| Chief Regulatory Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Corporate Affairs & Corporate Strategy | 1.3yrs | Nessun dato | Nessun dato | |
| Senior VP of Finance & Financial Planning | less than a year | Nessun dato | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Research and Early Development | no data | Nessun dato | Nessun dato | |
| Investor Relations Officer | no data | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di OVID non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.2yrs | US$1.93m | 2.02% $ 8.6m | |
| CEO, President & Director | less than a year | US$1.02m | 0.011% $ 45.6k | |
| Chairman of the Scientific & Clinical Advisory Board | 5.2yrs | Nessun dato | Nessun dato | |
| Independent Director | 9yrs | US$86.27k | 0% $ 0 | |
| Lead Independent Director | 10.6yrs | US$105.75k | 0.0012% $ 5.0k | |
| Member of Scientific & Clinical Advisory Board | 9.4yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.9yrs | Nessun dato | Nessun dato | |
| Independent Director | 4.7yrs | US$69.94k | 0.0024% $ 10.0k | |
| Member of Scientific Advisory Board | 1.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.4yrs | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di OVID sono considerati esperti (durata media dell'incarico 3.5 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/22 12:22 |
| Prezzo dell'azione a fine giornata | 2026/06/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Ovid Therapeutics Inc. è coperta da 16 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |